HIV/AIDS

Infectious Diseases
10
Pipeline Programs
7
Companies
17
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
1
2
5
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 21 programs with unclassified modality

On Market (1)

Approved therapies currently available

U
METFORMIN HYDROCHLORIDEApproved
metformin
Unknown Company
oral2018

Competitive Landscape

7 companies ranked by most advanced pipeline stage

GS
Gilead SciencesFOSTER CITY, CA
13 programs
1
2
4
Digital pillPhase 41 trial
Enhanced PrEP AdherencePhase 4
Enhanced PrEP AdherencePhase 41 trial
bictegravir/emtricitabine/tenofovir alafenamidePhase 41 trial
TDF/FTC 300mg/200mg fixed-dose combination tabletsPhase 31 trial
+8 more programs
Active Trials
NCT03343223Completed234Est. Feb 2019
NCT05111119Completed53Est. Aug 2024
NCT06353295Active Not Recruiting140Est. Jun 2026
+5 more trials
M&
Merck & Co.RAHWAY, NJ
1 program
1
MetforminPhase 2/31 trial
Active Trials
NCT04500678Unknown38Est. Dec 2022
Allergy Therapeutics
Allergy TherapeuticsUK - West Sussex
2 programs
1
Maraviroc 300 mg tabletPhase 11 trial
Digital PillN/A1 trial
Active Trials
NCT04065347CompletedEst. May 2023
NCT02346084CompletedEst. Mar 2016
Bristol Myers Squibb
2 programs
EfavirenzN/A1 trial
Impact of Hyperbilirubinemia Among HIV Patients Treated With AtazanavirN/ASmall Molecule1 trial
Active Trials
NCT02426866Completed29,612Est. Jan 2015
NCT02532673Completed1,200Est. May 2015
City Therapeutics
City TherapeuticsMA - Cambridge
2 programs
Enhanced Peer InterventionN/A1 trial
Patient NavigationN/A1 trial
Active Trials
NCT01616940CompletedEst. Mar 2014
NCT02259634TerminatedEst. Apr 2015
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
Door-to-doorN/A1 trial
Active Trials
NCT01459120Completed1,800Est. Feb 2012
Cipher Pharmaceuticals
Cipher PharmaceuticalsON - Mississauga
1 program
PEBRA modelN/A1 trial
Active Trials
NCT03969030CompletedEst. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
Gilead Sciencesbictegravir/emtricitabine/tenofovir alafenamide
Gilead SciencesDigital pill
Gilead SciencesEnhanced PrEP Adherence
Gilead SciencesTDF/FTC 300mg/200mg fixed-dose combination tablets
Merck & Co.Metformin
Gilead SciencesChAdOx1.HTI
Allergy TherapeuticsMaraviroc 300 mg tablet
Gilead SciencesP4P intervention
Gilead SciencesMaking PrEP Smart
Allergy TherapeuticsDigital Pill
Cipher PharmaceuticalsPEBRA model
Gilead SciencesIntervention Group
Bristol Myers SquibbEfavirenz
Bristol Myers SquibbImpact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir
City TherapeuticsPatient Navigation

Showing 15 of 17 trials with date data

Clinical Trials (17)

Total enrollment: 33,881 patients across 17 trials

NCT04249037Gilead Sciencesbictegravir/emtricitabine/tenofovir alafenamide

Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

Start: Dec 2020Est. completion: Jul 202310 patients
Phase 4Terminated
NCT03842436Gilead SciencesDigital pill

Feasibility and Acceptability of Digital Pills to Monitor PrEP Adherence in MSM With Substance Use

Start: Oct 2018Est. completion: Apr 202016 patients
Phase 4Completed
NCT02167386Gilead SciencesEnhanced PrEP Adherence

PrEPared and Strong: Clinic-Based PrEP for Black MSM

Start: Mar 2015Est. completion: Feb 2018204 patients
Phase 4Completed
NCT05813964Gilead SciencesTDF/FTC 300mg/200mg fixed-dose combination tablets

Efficacy, Acceptability and Safety of Event-driven HIV PrEP Using TAF/FTC in MSM in Thailand and France.

Start: Jun 2024Est. completion: May 2027524 patients
Phase 3Recruiting
NCT04500678Merck & Co.Metformin

Impact of Metformin on Immuno-virologic Parameters in HIV

Start: Feb 2019Est. completion: Dec 202238 patients
Phase 2/3Unknown
NCT04364035Gilead SciencesChAdOx1.HTI

Safety, Tolerability and Immunogenicity of MVA.HTI and ChAdOx1.HTI With Vesatolimod in HIV-1 Positive Patients

Start: Feb 2020Est. completion: Dec 202250 patients
Phase 2Completed
NCT02346084Allergy TherapeuticsMaraviroc 300 mg tablet

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

Start: Jan 2015Est. completion: Mar 2016
Phase 1Completed
NCT06353295Gilead SciencesP4P intervention

Community-based, Peer-delivered PrEP for Female Sex Workers in Rural Uganda: The Peers for PrEP (P4P) Study

Start: Apr 2024Est. completion: Jun 2026140 patients
N/AActive Not Recruiting
NCT05111119Gilead SciencesMaking PrEP Smart

Making PrEP Smart: An HIV Testing and PrEP Electronic Support Tool ("SmartPrEP" App) for Women on PrEP

Start: Feb 2022Est. completion: Aug 202453 patients
N/ACompleted
NCT04065347Allergy TherapeuticsDigital Pill

Quantification of Tenofovir Alafenamide Adherence (QUANTI-TAF)

Start: Nov 2019Est. completion: May 2023
N/ACompleted
NCT03969030Cipher PharmaceuticalsPEBRA model

Peer-Educator-coordinated vs Nurse-coordinated ART Refill for Adolescents and Young Adults Living With HIV in Lesotho

Start: Nov 2019Est. completion: Apr 2021
N/ACompleted
NCT03343223Gilead SciencesIntervention Group

Rural PrEP Delivery

Start: Feb 2018Est. completion: Feb 2019234 patients
N/ACompleted
NCT02426866Bristol Myers SquibbEfavirenz

Risk of CV Events With EFV vs. EFV-free Regimens

Start: Dec 2014Est. completion: Jan 201529,612 patients
N/ACompleted
NCT02532673Bristol Myers SquibbImpact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir

Impact of Hyperbilirubinemia Among HIV Patients Treated With Atazanavir

Start: Aug 2014Est. completion: May 20151,200 patients
N/ACompleted
NCT02259634City TherapeuticsPatient Navigation

Study on the Impact of Patient Navigators on the Health Education and Quality of Life in Formerly Incarcerated Patients

Start: Jun 2014Est. completion: Apr 2015
N/ATerminated
NCT01459120Mission TherapeuticsDoor-to-door

Comparison of Door-to-door Versus Community Gathering to Provide HIV Counseling and Testing Services in Rural Lesotho

Start: Oct 2011Est. completion: Feb 20121,800 patients
N/ACompleted
NCT01616940City TherapeuticsEnhanced Peer Intervention

Minority AIDS Initiative Retention and Re-Engagement Project

Start: Sep 2011Est. completion: Mar 2014
N/ACompleted

Related Jobs in Infectious Diseases

Director, Program Management

Metaphore Biotechnologies
Somerville, MA USA
8h ago
$179K - $237K/yr

Executive Director, Global Medical Expert HIV Prevention - GMA Virology & Inflammation

Gilead Sciences
United States - Field
20h ago
$317K - $411K/yr

Sr. Engineer, Process Systems (Contract)

VaxCyte
Visp, Valais, Switzerland
23h ago

Contract Senior Research Associate, Protein Science

Keros Therapeutics
Lexington, Massachusetts, United States
Yesterday

Director, Health Economics & Outcomes Research (HEOR)

VaxCyte
San Carlos, California, United States
Yesterday
$242K - $282K/yr

Senior Manager, Contract Account Performance Specialist, Contract Strategy

Pfizer
Remote
Yesterday
$124K - $207K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 33,881 patients
7 companies competing in this space

Related Indications

HIV Infections(449)COVID-19(223)Hepatitis C(191)Influenza(173)HIV(138)HIV-1-infection(115)Hepatitis C, Chronic(94)Chronic Hepatitis B(93)Chronic Hepatitis C(91)Covid19(79)